These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30753377)

  • 1. Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
    Hisamatsu T; Matsumoto T; Watanabe K; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2019 Sep; 13(9):1097-1104. PubMed ID: 30753377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
    Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?
    Fiorino G; Danese S
    J Crohns Colitis; 2016 Nov; 10(11):1257-1258. PubMed ID: 27389085
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
    Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
    Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
    J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE; Aloi M; de Ridder L; Croft NM; Koletzko S; Levine A; Turner D; Veereman G; Neyt M; Bigot L; Ruemmele FM; Russell RK;
    BMJ Open; 2020 Jul; 10(7):e034892. PubMed ID: 32611737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
    Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Severe lymphopenia in a patient with Crohn's disease].
    Monasterio C; Kreisel W; Hasselblatt P
    Internist (Berl); 2018 Aug; 59(8):857-860. PubMed ID: 29356833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index.
    Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Italia A; Morino M; Saracco GM; Astegiano M
    Scand J Gastroenterol; 2019 Nov; 54(11):1339-1345. PubMed ID: 31692395
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
    J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery.
    Barnes EL; Goldin A; Winter RW; Collins E; Cao B; Carrellas M; Crowell AM; Korzenik JR
    Dig Dis Sci; 2016 Nov; 61(11):3261-3269. PubMed ID: 27639871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
    Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
    J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.